The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau PET uptake occurs at a later stage and age than amyloid Pet and is more closely associated with cognitive dysfunction than amyloid-PET.(442, 443)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“robust evidence indicates that cerebral Aβ accumulation is one of the earliest mechanistic alterations of the whole pathophysiological dynamic of AD (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, CSF and positron emission tomography longitudinal studies support the hypothetical pathophysiological model of AD for which amyloidosis proceeds, either promoting or being permissive to the spreading of tau pathology that is likely to drive disease clinical evolution (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several genetic data studies (306 autosomal dominant mutations plus the APP gene duplication and trisomy 21) and multimodal biomarker studies indicate that an imbalance between Aβ production and clearance plays a critical and early role in AD pathogenesis (104–106,113,114).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“A large amount of evidence also supports the hypothesis that cerebral Aβ deposition begins decades before AD clinical onset and prior to cortical spreading of tau pathology.”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 2×
“Among individuals with dementia, syndromic diagnoses followed established criteria for FTD syndromes (Gorno-Tempini et al., 2011; Rascovsky et al., 2011), probable DLB (McKeith et al., 2017), and AlzCS (McKhann et al., 1984, 2011; Jack et al., 2018).”
BackgroundMethodSelf-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · cited 15×
“Participants were assigned a diagnosis of cognitively unimpaired (defined as not MCI or dementia), MCI (Petersen, 2004), or dementia (American Psychiatric Association, 1994) using established criteria.”
InfluentialSelf-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“Among individuals with dementia, syndromic diagnoses followed established criteria for FTD syndromes (Gorno-Tempini et al., 2011; Rascovsky et al., 2011), probable DLB (McKeith et al.”
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 3×
“Amyloid PET imaging was performed with Pittsburgh Compound B (PIB) (Klunk et al., 2004) and tau PET with flortaucipir (Chien et al.”
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
“35 40 Second, when it does occur, it is often due to quantitative values close to cutpoints that may fall on one side versus the other owing to measurement variation.”
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In the clinical setting, neuroimaging of sporadic Alzheimer’s patients show the increased cortical tau-PET ligand retention only in the presence of Aβ accumulation, which is also associated with cortical atrophy in AD.(110) In addition, longitudinal studies idenfied that antecedent Aβ aggregates could successfully pre…”
BackgroundThe β-Secretase BACE1 in Alzheimer’s Disease
Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401
“…studies on the timing of the biomarker’s changes in sporadic or autosomaldominant AD suggest that CSF p-tau increases earlier in the disease than tau PET (Bateman et al, 2012; Toledo et al, 2013; Johnson et al, 2016; Quiroz et al, 2018; Gordon et al, 2019; Jack et al, 2019; Mattsson et al, 2019).”
BackgroundHow Can Hearing Loss Cause Dementia?
Griffiths, T. D., Lad, M., Kumar, S., Holmes, E., McMurray, B., Maguire, E. A., Billig, A. J., & Sedley, W. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.003 · Cited by 369
“Increasingly, clinical work has used biomarkers of AD pathology in cerebrospinal fluid (Jack and Holtzman, 2013) and brain imaging of biomarkers (Jack et al., 2019; Morris et al., 2016; Pereira et al., 2019) to provide estimates of the extent and distribution of disease.”
BackgroundOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311
Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease
d‘Errico, P., & Meyer-Luehmann, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00265 · Cited by 175
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras-Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 147
Self-citationOssenkoppele, R., Salvadó, G., Janelidze, S., Binette, A. P., Bali, D., Karlsson, L., Palmqvist, S., Mattsson, N., Stomrud, E., Therriault, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00835-z · Cited by 152
“…tau-PET scans are relatively rare in CU individuals (that is, ~5–10% among Aβ-positive CU individuals in a temporal meta-region of interest) 3,4 , and post-mortem studies have indicated that a positive [ 18 F]flortaucipir tau-PET scan (quantitatively or by visual read) represents tau…”
Self-citationMild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
Johansson, M., Stomrud, E., Insel, P. S., Leuzy, A., Johansson, P., Smith, R. A., Ismail, Z., Janelidze, S., Palmqvist, S., van Westen, D., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01206-z · Cited by 153
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies
Ferreira, D., Przybelski, S. A., Lesnick, T. G., Lemstra, A. W., Londos, E., Blanc, F., Nedelska, Z., Schwarz, C. G., Graff-Radford, J., Senjem, M. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010943 · Cited by 132
“33 for AV-1451, as previously described.(23)”
Self-citationAmyloid-β: a potential link between epilepsy and cognitive decline
Romoli, M., Sen, A., Parnetti, L., Calabresi, P., & Costa, C. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00505-9 · Cited by 154
Tau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137
Ossenkoppele, R., Singleton, E. H., Groot, C., Dijkstra, A. A., Eikelboom, W. S., Seeley, W. W., Miller, B., Laforce, R. J., Scheltens, P., Papma, J. M., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4417 · Cited by 122
Ossenkoppele, R., Reimand, J., Smith, R., Leuzy, A., Strandberg, O., Palmqvist, S., Stomrud, E., Zetterberg, H., Initiative, T. A. D. N., Scheltens, P., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114398 · Cited by 130
“In line with previous work from our group and others (Cho et al, 2016; Ossenkoppele et al, 2018; Jack et al, 2019; Leuzy et al, 2020; Ossenkoppele et al, 2020a), we used a temporal meta-ROI (Jack et al, 2017) comprising a weighted average of entorhinal, amygdala, parahippocampal, fusiform and…”
MethodHearing impairment is associated with cognitive decline, brain atrophy and tau pathology
Wang, H.-F., Zhang, W., Rolls, E. T., Li, Y., Wang, L., Ma, Y., Kang, J., Feng, J., Yu, J., & Cheng, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104336 · Cited by 141
Determining Amyloid-β Positivity Using18F-AZD4694 PET Imaging
Therriault, J., Benedet, A. L., Pascoal, T. A., Savard, M., Ashton, N. J., Chamoun, M., Tissot, C., Lussier, F., Kang, M. S., Bezgin, G., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245209 · Cited by 121
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
“A memory domain z-score was calculated as the mean of these three component tests (Jack et al., 2019a).”
BackgroundMethodInfluentialSelf-citationKamondi, A., Grigg-Damberger, M. M., Löscher, W., Tanila, H., & Horvath, A. A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00932-4 · Cited by 127
“People with AD with comparable amyloid plaque burden can still differ in their p-tau level 205,206 , which might have an effect on their susceptibility to seizures.”
Guo, T., Korman, D., Baker, S. L., Landau, S. M., & Jagust, W. J. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.06.029 · Cited by 105
“In fact, our data echo previous fi ndings that brain tau is rarely substantially elevated in the absence of abnormal A b (28,37,38), and that even in A b – individuals, higher A b and faster A b deposition predict later brain tau (9 – 11).”
Relationship between amyloid and tau levels and its impact on tau spreading
Doré, V., Krishnadas, N., Bourgeat, P., Huang, K., Li, S., Burnham, S., Masters, C. L., Fripp, J., Villemagne, V. L., & Rowe, C. C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05191-9 · Cited by 93
Therriault, J., Pascoal, T. A., Benedet, A. L., Tissot, C., Savard, M., Chamoun, M., Lussier, F., Kang, M. S., Berzgin, G., Wang, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011416 · Cited by 91
“For the study’s primary hypotheses, individuals were grouped into 1 of 4 AD biomarker categories based on their AD biomarker abnormality: A−T−: negative AD biomarkers; A+T−: Alzheimer pathologic change; A−T+: non-Alzheimer pathologic change; A+T+: biological AD.(12,14,25) Because our primary hypothesis was to determin…”
BackgroundAssociations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid
Albrecht, D., Isenberg, A. L., Stradford, J., Monreal, T. K., Sagare, A. P., Pachicano, M., Sweeney, M. D., Toga, A. W., Zloković, B. V., Chui, H. C., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1230-20.2020 · Cited by 91
“Numerous postmortem and in vivo human studies posit an interactive model where early amyloid accumulation potentially promotes tau tangle formation (Ingelsson et al., 2004; Hanseeuw et al., 2019; Jack et al., 2019).”
Dhaynaut, M., Sprugnoli, G., Cappon, D., Macone, J., Sanchez, J. S., Normandin, M. D., Guehl, N. J., Koch, G., Paciorek, R., Connor, A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215072 · Cited by 88
“The annual rate of change in global and regional A (cid:2) and p-Tau ratio is rarely decreasing and is generally either nonsignificant or positive, typically on the order of 0.05 units/year, and asymptotes in patients with cognitive deficits and high A (cid:2) and p-Tau levels [5, 17, 18].”
InfluentialAPOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80
“Similarly, it has been suggested that tau pathology begins to accelerate, particularly in neocortex, at some point after an individual becomes amyloid positive [15, 71].”
BackgroundAging-associated sensory decline and Alzheimer’s disease
Hong, S., Baek, S.-H., Lai, M. K. P., Arumugam, T. V., & Jo, D.-G. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00776-y · Cited by 76
Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults
Harrison, T. M., Du, R., Klencklen, G., Baker, S. L., & Jagust, W. J. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12249 · Cited by 75
The complex pathway between amyloid β and cognition: implications for therapy
Jagust, W. J., Teunissen, C. E., & DeCarli, C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00128-x · Cited by 71
Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 73
“However, also consistent with previous studies [42, 63, 64], we found that tau (CSF pTau/Aβ40 or tau PET) was rarely (5.”
ResultKshirsagar, S., Sawant, N. A., Morton, H., Reddy, A. P., & Reddy, P. H. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab262 · Cited by 69
RetractedChin, K. S., Yassi, N., Churilov, L. P., Masters, C. L., & Watson, R. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.030 · Cited by 67
A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
Coomans, E. M., Verberk, I. M. W., Ossenkoppele, R., Verfaillie, S. C. J., Visser, D., Gouda, M., Tuncel, H., Wolters, E. E., Timmers, T., Windhorst, A. D., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264279 · Cited by 65
“Both plasma pTau181 and tau-PET are closely associated with amyloid-β (Aβ) pathology(7,19).”
BackgroundResultRegional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults
Chen, X., Cassady, K. E., Adams, J. N., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2111-20.2020 · Cited by 64
“This early EC tau increases with age and has been reported in individuals without Ab pathology (Sonnen et al., 2011; Jack et al., 2019; Schöll et al., 2019).”
BackgroundPichet Binette, A., Theaud, G., Rheault, F., Roy, M., Collins, D. L., Levin, J., Mori, H., Lee, J. H., Farlow, M. R., Schofield, P., et al. (2021) · eLife · doi:10.7554/elife.62929 · Cited by 56
“, 2021) and that the presence of Ab is needed to facilitate the accumulation of tau (Jack et al., 2019), we considered the same proportion of Ab-positive and tau-positive participants in PREVENT-AD.”
BackgroundTowards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61
Self-citationGhirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59
Self-citationMcDade, E. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001131 · Cited by 64
Iaccarino, L., La Joie, R., Edwards, L., Strom, A., Schonhaut, D. R., Ossenkoppele, R., Pham, J., Mellinger, T., Janabi, M., Baker, S. L., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhaa184 · Cited by 54
“Tau-PET studies have demonstrated a tighter relationship between NFT accumulation and neurodegeneration, with regional tau PET uptake correlating with atrophy, glucose hypometabolism, and clinical deficits across the spectrum of disease severity (Bischof et al. 2016; Brier et al. 2016; Cho et al. 2016; Dronse et al. 2…”
BackgroundThe impact of demographic, clinical, genetic, and imaging variables on tau PET status
Ossenkoppele, R., Leuzy, A., Cho, H., Sudre, C. H., Strandberg, O., Smith, R., Palmqvist, S., Mattsson-Carlgren, N., Olsson, T., Jögi, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05099-w · Cited by 50
Weinstein, G., O’Donnell, A., Davis‐Plourde, K. L., Zelber‐Sagi, S., Ghosh, S., DeCarli, C. S., Thibault, E. G., Sperling, R. A., Johnson, K. A., Beiser, A., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215409 · Cited by 55
“Furthermore, tau deposition in these brain regions are highly correlated with early AD clinical phenotypes [72, 74–76].”
Association of amyloid-β CSF/PET discordance and tau load 5 years later
Reimand, J., Collij, L., Scheltens, P., Bouwman, F., Ossenkoppele, R., & Initiative, F. T. A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010739 · Cited by 50
Mechanistic new insights of flavonols on neurodegenerative diseases
Tahir, M. S., Almezgagi, M., Zhang, Y., Bashir, A., Abdullah, H. M., Gamah, M., Wang, X., Zhu, Q., Shen, X., Ma, Q., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111253 · Cited by 59
Naude, J., Wang, M., Leon, R., Smith, E. E., & Ismail, Z. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.02.006 · Cited by 52
Frontotemporal dementias: main syndromes and underlying brain changes
Piguet, O., & Kumfor, F. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000792 · Cited by 46
Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Hansson, O., Nordberg, A., Frisoni, G. B., Garibotto, V., & Ossenkoppele, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05118-w · Cited by 45
Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae183 · Cited by 52
“65,66 The specification of ‘neocortical’ tau as opposed to tau in general is to account for the limbic variant of Alzheimer’s disease wherein associated clinical and pathologic findings localize to the limbic system, 67,68 thus qualifying for LANS.”
BackgroundSelf-citationAdvances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 51
Cai, Y. Q., Du, J., Li, A., Zhu, Y., Xu, L., Sun, K., Ma, S., Guo, T., & Initiative, A. D. N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01178-w · Cited by 48
“Furthermore, many studies reported that abnormal tau tangles outside the entorhinal cortex were rarely observed in the absence of substantial cortical Aβ burden [9, 20, 21, 25, 42], and larger Aβ burden was strongly related to more rapid tau accumulation over time [5, 10, 11, 20].”
BackgroundMalpetti, M., Joie, R. L., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263694 · Cited by 45
Cooper, L. L., O’Donnell, A., Beiser, A., Thibault, E. G., Sanchez, J. S., Benjamin, E. J., Hamburg, N. M., Vasan, R. S., Larson, M. G., Johnson, K. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1261 · Cited by 47
Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies
Diaz‐Galvan, P., Przybelski, S. A., Algeciras‐Schimnich, A., Figdore, D. J., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13653 · Cited by 43
Self-citationJin, P., Xu, J., Liao, Z., Zhang, Y., Wang, Y., Sun, W., & Yu, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1099333 · Cited by 42
“This may be the result of differences in sample selection, since abnormal tau deposition has to essentially occur in addition to abnormal Aβ deposition (75, 76).”
BackgroundCryo-EM Structures of Chronic Traumatic Encephalopathy Tau Filaments with PET Ligand Flortaucipir
Shi, Y., Ghetti, B. F., Goedert, M., & Scheres, S. H. W. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168025 · Cited by 44
Groot, C., Doré, V., Robertson, J. S., Burnham, S. C., Savage, G. R., Ossenkoppele, R., Rowe, C. C., & Villemagne, V. L. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.017 · Cited by 41
Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model
Therneau, T. M., Knopman, D. S., Lowe, V. J., Botha, H., Graff‐Radford, J., Jones, D. T., Vemuri, P., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118440 · Cited by 45
“Further, there are very few participants with highly elevated tau in the MCSA sample as previously reported (Jack et al., 2019; Lowe et al., 2019a).”
Self-citationNoise as a cause of neurodegenerative disorders: molecular and cellular mechanisms
Manukyan, A. L. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05948-6 · Cited by 41
Josephs, K. A., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8076 · Cited by 42
“…have tried to understand the relationship between tau and a myloid-β using PET ( 13 , 22 , 23 ), demonstrating that a myloid-β is required for high tau PET uptake ( 23 ) and that a myloid-β is more strongly associated with tau in cortical regions compared with medial temporal regions ( 13 ).”
BackgroundSelf-citationFerreira, D., Mohanty, R., Murray, M. E., Nordberg, A. K., Kantarci, K., & Westman, E. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01471-z · Cited by 40
“Briefly, the ‘accuracy-based cut point’ is increasingly used in the field but is conservative and is based on a meta-region of interest (ROI) that includes the entorhinal cortex and several other cortical areas (see Table 1 for a description of the meta-ROI) [14].”
BackgroundMethodSelf-citationLewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype
Buciuc, M., Whitwell, J. L., Kasanuki, K., Graff‐Radford, J., Machulda, M. M., Duffy, J. R., Strand, E. A., Lowe, V. J., Graff‐Radford, N. R., Rush, B. K., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25979 · Cited by 39
Self-citationTeng, E., Manser, P. T., Sanabria Bohorquez, S., Wildsmith, K. R., Pickthorn, K., Baker, S. L., Ward, M., Kerchner, G. A., & Weimer, R. M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00937-x · Cited by 30
“In contrast, for Aβ PET, which has a more bimodal distribution between AD patients and controls [47], the same threshold for high versus low Αβ pathology may be useful for both diagnosis and prognosis [48].”
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
Bullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01048-x · Cited by 34
“Additionally, similar bivariate associations between amyloid-beta and tau have been reported for other PET tracers: 18F-florbetaben and 18F-flortaucipir [25], 18F-NAV4694 and 18F-MK6240 [30], 11C-PiB and 18F-flortaucipir [31], and 18F-florbetapir and 18F-flortaucipir [5].”
BackgroundAPOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression
Dincer, A., Chen, C. D., McKay, N. S., Koenig, L. N., McCullough, A. A., Flores, S. E., Keefe, S., Schultz, S. A., Feldman, R. L., Joseph‐Mathurin, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7646 · Cited by 39
Smith, R., Hägerström, D., Pawlik, D., Klein, G., Jögi, J., Ohlsson, T., Stomrud, E., & Hansson, O. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1323 · Cited by 33
[18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
Chiotis, K., Savitcheva, I., Poulakis, K., Saint‐Aubert, L., Wall, A. E., Antoni, G., & Nordberg, A. K. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0815-4 · Cited by 33
β-Amyloid PET and 123 I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia
Chen, Q., Lowe, V. J., Boeve, B. F., Przybelski, S. A., Miyagawa, T., Senjem, M. L., Jack, C. R., Lesnick, T. G., Kremers, W. K., Fields, J. A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011454 · Cited by 33
Self-citationA Visual Interpretation Algorithm for Assessing Brain Tauopathy with18F-MK-6240 PET
Seibyl, J. P., DuBois, J. M., Racine, A. M., Collins, J. A., Guo, Q., Wooten, D., Stage, E., Cheng, D., Gunn, R. N., Porat, L., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264371 · Cited by 33
“(15) showed slightly higher sensitivity and specificity than did Braak 1–2 or Braak 5–6 analyses, although the difference did not achieve statistical significance (P 5 0.”
BackgroundTarawneh, H. Y., Jayakody, D. M. P., Sohrabi, H. R., Martins, R. N., & Mulders, W. H. A. M. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220035 · Cited by 33
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 36
“54-60 Even in a predominantly MCI cohort, 72% of those with elevated flortaucipir signal limited to the medial temporal region (likely an earlier measure of tau positivity than neocortical signal) also had elevated neocortical amyloid-PET signal.”
BackgroundSattarov, R., Havers, M., Orbjörn, C., Stomrud, E., Janelidze, S., Laurell, T., & Mattsson, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-75406-0 · Cited by 33
Almeida, F., Santos, A. C., Jesus, T., Coelho, A., Quintas-Neves, M., Gauthreaux, K. M., Mock, C., Kukull, W. A., Crary, J. F., & Oliveira, T. G. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14191 · Cited by 32
Development, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
Shuping, J., Matthews, D. C., Adamczuk, K., Scott, D., Rowe, C. C., Kreisl, W. C., Johnson, S. C., Lukic, A. S., Johnson, K. A., Rosa‐Neto, P., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12372 · Cited by 37
Coomans, E. M., de Koning, L. A., Rikken, R. M., Verfaillie, S. C. J., Visser, D., den Braber, A., Tomassen, J., Beek, M. H. C. T. V., Collij, L. E., Lemstra, A. W., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207794 · Cited by 30
Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
Rullmann, M., Brendel, M., Schroeter, M. L., Saur, D., Levin, J., Perneczky, R. G., Tiepolt, S., Patt, M., Mueller, A., Villemagne, V. L., et al. (2022) · Biomolecules · doi:10.3390/biom12030458 · Cited by 29
“This finding is consistent with the hypothesis that tau is a significant impetus of the AD progression [4,23,24] and is in line with the known floor effects of the MMSE in advanced disease stages.”
ResultImplication of tau propagation on neurodegeneration in Alzheimer’s disease
Lamontagne-Kam, D., Ulfat, A. K., Hervé, V., Vu, T.-M., & Brouillette, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1219299 · Cited by 31
“Moreover, there is a growing body of evidence suggesting that substantial inter-individual variabilities in the pattern and intensity of tau signal may be more common than previously expected in affected AD brain regions (Murray et al., 2011; Scholl et al., 2017; Hanseeuw et al., 2019; Jack et al., 2019; Lowe et al.,…”
BackgroundTau-related grey matter network breakdown across the Alzheimer’s disease continuum
Pelkmans, W., Ossenkoppele, R., Dicks, E., Strandberg, O. T., Barkhof, F., Tijms, B. M., Pereira, J. B., & Hansson, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00876-7 · Cited by 29
Badachhape, A., Working, P. K., Srivastava, M., Bhandari, P., Stupin, I. V., Devkota, L., Tanifum, E. A., Annapragada, A., & Ghaghada, K. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-73233-7 · Cited by 26
Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome
Zammit, M. D., Tudorascu, D. L., Laymon, C. M., Hartley, S. L., Ellison, P. A., Zaman, S. H., Ances, B. M., Johnson, S. C., Stone, C. K., Sabbagh, M. N., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102740 · Cited by 25
Risacher, S. L., & Apostolova, L. G. (2023) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001248 · Cited by 26
Kshirsagar, S., Reddy, A. P., & Reddy, P. H. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102038 · Cited by 25
The many faces of globular glial tauopathy: A clinical and imaging study
Buciuc, M., Koga, S., Pham, N. T. T., Duffy, J. R., Knopman, D. S., Ali, F., Boeve, B. F., Graff‐Radford, J., Botha, H., Lowe, V. J., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15603 · Cited by 26
“48 used to define PiB- PET positivity [25].”
MethodSelf-citationDilcher, R., Wall, S., Groß, M., Katzdobler, S., Wagemann, O., Palleis, C., Weidinger, E., Fietzek, U. M., Bernhardt, A., Kurz, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14185 · Cited by 24
“3,4 Tauopathies are typically classified into primary and secondary tauopathies based on the molecular composition of tau aggregates and the co-occurrence of other protein deposits, suchasbetaamyloidplaquepathologyinAlzheimer’sdisease (AD).”
BackgroundBoyton, I., Valenzuela, S. M., Collins‐Praino, L. E., & Care, A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.004 · Cited by 23
Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition
Ramanan, V. K., Wang, X., Przybelski, S. A., Raghavan, S., Heckman, M. G., Batzler, A. J., Kosel, M., Hohman, T. J., Knopman, D. S., Graff‐Radford, J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa159 · Cited by 24
“…on tau deposition in aging and neurodegenerative disease are presumed to be complex and multifactorial. b-amyloidosis is a risk factor for tau accumulation within and outside of the medial temporal lobe (He et al., 2018; Jack et al., 2018, 2019; Pontecorvo et al., 2019; Ramanan et al., 2019).”
BackgroundMethodInfluentialSelf-citationLongitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes
Whitwell, J. L., Tosakulwong, N., Schwarz, C. C., Senjem, M. L., Spychalla, A. J., Duffy, J. R., Graff-Radford, J., Machulda, M. M., Boeve, B. F., Knopman, D. S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010948 · Cited by 24
“48.(28) For flortaucipir-PET, all voxels in the MPRAGE space image were divided by median uptake in cerebellar crus gray matter to create an SUVR image.”
MethodSelf-citationLongitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
Chen, Q., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Lesnick, T. G., Botha, H., Knopman, D. S., Graff‐Radford, J., Savica, R., Jones, D. T., et al. (2022) · Movement Disorders · doi:10.1002/mds.28973 · Cited by 23
Self-citationFerreira, D., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Diaz‐Galvan, P., Graff‐Radford, J., Senjem, M. L., Fields, J. A., Knopman, D. S., Jones, D. T., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201579 · Cited by 23
“25 for flortaucipir.(18) In total, MCALT atlases provided estimations of PiB and flortaucipir SUVr across 23 ROIs (Figure 1 and eTable 1 in the Supplement).”
BackgroundSelf-citationLong, J., Qin, F., Luo, J., Zhong, G., Huang, S., Jing, L., Yi, T., Liu, J., & Jiang, N. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107026 · Cited by 22
Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18
Fu, J. F., Lois, C., Sanchez, J. S., Becker, J. A., Rubinstein, Z. B., Thibault, E. G., Salvatore, A. N., Sari, H., Farrell, M. E., Guehl, N. J., et al. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221142139 · Cited by 18
Metadata
- Authors
- Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., Kantarci, K., Lowe, V. J., Vemuri, P., Mielke, M. M., Fields, J. A., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Gunter, J. L., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Department of Neurology, Mayo Clinic, Rochester, MN, USA
- Corresponding author
- Jack, Clifford R
- ORCID
- Jack, Clifford R
- Wiste, Heather J
- Botha, Hugo
- Weigand, Stephen D
- Therneau, Terry M
- Knopman, David S
- Jones, David T
- Ferman, Tanis J
- Boeve, Bradley F
- Kantarci, Kejal
- Lowe, Val J
- Vemuri, Prashanthi
- Mielke, Michelle M
- Fields, Julie A
- Machulda, Mary M
- Schwarz, Christopher G
- Senjem, Matthew L
- Gunter, Jeffrey L
- Petersen, Ronald C
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-09
- Volume
- 142
- Issue
- 10
- Pages
- 3230-3242
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6763736
- OpenAlex
- W2972315303
- Cited by
- 200
- References
- 93
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 31 · 2023: 34 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 3
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R37 AG011378, RO1 AG041851, R01 AG056366, R01 NS097495, U01 AG06786, R01 AG034676, P50 AG016574)
- GHR Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- tau PET, amyloid-beta, bivariate distributions, mild cognitive impairment, frontotemporal dementia, dementia with Lewy bodies, Alzheimer's disease, tauopathy, amyloidosis, standardized uptake value ratio, cognitive aging, neurodegeneration biomarkers, Mayo Clinic Study of Aging, clinical syndromes
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amyloid, Amyloidosis, Brain, Cognition, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurocognitive Disorders, Tauopathies, Positron-Emission Tomography, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.